RECODE · 연구동향생성일 2026-10-31

연구동향

기준 논문: 알츠하이머병에 대한 근거중심 처방

J Korean Med Assoc 52(4):417-425 · 2009

검색 방법

이 논문의 제목과 주제어를 바탕으로 이 논문이 속한 연구 분야를 묻는 질문을 만들어 ReviewFast에 넣어 2026-10-31에 검색했습니다. ReviewFast가 PubMed를 검색하고, AI 모델(Jev)이 제목과 초록을 읽어 질문과의 관련도를 매긴 뒤 주제별로 묶었습니다.

10,306편 검색→1,942편 판독→225편 선별 (관련도 0.5 이상)

질문과 PubMed 검색식 보기질문: Evidence-based pharmacological treatment of Alzheimer disease with cholinesterase inhibitors and memantine (Alzheimer*[tiab] OR "Alzheimer disease"[mh] OR "Alzheimer's disease"[tiab]) AND (cholinesterase inhibitor*[tiab] OR donepezil[tiab] OR rivastigmine[tiab] OR galantamine[tiab] OR memantine[tiab] OR "Cholinesterase Inhibitors"[mh] OR "Memantine"[mh]) AND (drug therapy[sh] OR treatment[tiab] OR therapeutic use[sh] OR pharmacotherapy[tiab])

출판 연도

2022: 5편520222023: 50편502024: 53편532025: 57편572026: 60편602026

선별된 225편의 출판 연도. 검색일(2026-10-31) 기준이며, 그 이후 논문은 들어 있지 않습니다.

주제별 논문

주제 이름은 ReviewFast가 초록의 단어로 자동으로 붙인 것입니다. 왼쪽 숫자는 관련도(0–1)입니다. RECODE 는 우리 연구팀 논문입니다.

01dementia · risk144편

  1. 0.94

    Efficacy and safety of a novel, extended-release rivastigmine transdermal patch (TW-4752N) in patients with Alzheimer's disease: A 24-week randomized, double-blind trial with a 28-week open-label extension

    Nakamura Y, Kurokawa T, Terashima S et al. · Journal of Alzheimer's disease : JAD · 2026

  2. 0.94

    Efficacy and safety of a transdermal donepezil patch in patients with mild-to-moderate Alzheimer's disease: A 24-week, randomized, multicenter, double-blind, parallel group, non-inferiority study

    Nakamura Y, Kim R, Nishiyama K et al. · Geriatrics & gerontology international · 2023

  3. 0.93

    Combined Effects of Donepezil and Memantine on Behavioral and Psychological Symptoms, Cognitive Function, and Daily Living Abilities in Patients With Alzheimer's Disease

    Tu H, Zhou S, Lin J · British journal of hospital medicine (London, England : 2005) · 2025

  4. 0.93

    Memantine in Korean Alzheimer's disease: A prospective real-world REMIND study

    Na S, Kim HS, Kim GH et al. · International psychogeriatrics · 2026

  5. 0.92

    Impact of dose and compliance of antidementia medications on long-term outcomes in Alzheimer's disease: a nationwide real-world study

    Kim T, Hong YJ, Kim M et al. · Alzheimer's research & therapy · 2026

  6. 0.92

    Effectiveness of acetylcholinesterase inhibitors and memantine in patients affected by severe dementia

    Zuliani G, Brombo G, Romagnoli T et al. · GeroScience · 2026

  7. 0.92

    Long-term effect of discontinuing anticholinesterase treatment on cognitive decline and mortality in Alzheimer's disease in France: a quasi-experiment and target trial emulation study

    Lecerf S, Guinebretiere O, Bentegeac R et al. · The Lancet regional health. Europe · 2026

  8. 0.92

    Dynamic associations of cholinesterase inhibitors and memantine with cognitive trajectories in individuals with Alzheimer's or mixed dementia: a real-world analysis using the quality registry SveDem

    Chen C, Mo M, Akerman M et al. · Alzheimer's research & therapy · 2025

  9. 0.92

    Efficacy and Safety of a Transdermal Donepezil Patch in Patients with Mild to Moderate Alzheimer's Disease: Open-Label, Extension Study

    Nakamura Y, Omori T, Kim R et al. · Journal of Alzheimer's disease : JAD · 2023

  10. 0.91

    Safety and efficacy of rivastigmine and memantine combined for treatment of patients with Alzheimer's disease: a retrospective study

    Wang H, Lv P · American journal of translational research · 2025

  11. 0.90

    Differential response to donepezil in MRI subtypes of mild cognitive impairment

    Diaz-Galvan P, Lorenzon G, Mohanty R et al. · Alzheimer's research & therapy · 2023

  12. 0.89

    Dynamic long-term modulation of cognition, brain structure and covariance networks in mild cognitive impairment due to AD by donepezil: A 36-month longitudinal study

    Chen Y, Tong Z, Wang H et al. · Journal of neurology · 2026

  13. 0.89

    A Multicentre, Randomised, Open-Label, Prospective Study to Estimate the Add-On Effects Of Memantine as Ebixa((R)) Oral Pump (Solution) on Language in Patients with Moderate to Severe Alzheimer's Disease Already Receiving Donepezil (ROMEO-AD)

    Kim HJ, Shim Y, Han HJ et al. · Neurology and therapy · 2023

  14. 0.89

    Long-Term Safety, Tolerability, and Efficacy of a Transdermal Donepezil Patch in Patients with Severe Alzheimer's Disease

    Nakamura Y, Narita K, Kim R et al. · Journal of Alzheimer's disease : JAD · 2023

  15. 0.88

    Comparative Effectiveness of Rivastigmine and Donepezil in Patients With Alzheimer's Disease: A Retrospective Cohort Study

    Abbas Raja A, Amjad A, Choudhary A et al. · Cureus · 2025

  16. 0.88

    Post Hoc Subgroup Analysis by Disease Severity in a Non-Inferiority Trial of Donepezil 27.5 mg Transdermal Formulation in Japanese Patients With Mild-to-Moderate Alzheimer Disease

    Nakamura Y, Tsushio T, Tanahashi M et al. · Alzheimer disease and associated disorders · 2026

  17. 0.88

    Therapeutic drug monitoring for dose optimization in Alzheimer's disease and in dementia with Lewy bodies: A randomized single-blinded clinical trial

    Fischer MHF, Zibrandtsen IC, Johannsen P et al. · Journal of Alzheimer's disease reports · 2024

  18. 0.87

    Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer s dementia

    Nielsen RE, Grontved S, Lolk A et al. · Medicine · 2022

  19. 0.87

    Combined use of Donepezil and Memantine increases the probability of five-year survival of Alzheimer's disease patients

    Yaghmaei E, Lu H, Ehwerhemuepha L et al. · Communications medicine · 2024

  20. 0.87

    Comparative assessment of donepezil memantine and sodium oligomannate on cognitive decline and neuroinflammation in early Alzheimer's disease

    Deng X, Zeng Y, Ding D · Pakistan journal of pharmaceutical sciences · 2026

  21. 0.87

    Functional Connectivity Alterations in the Cholinergic Neural Circuits of Patients With Alzheimer's Disease: A Donepezil Intervention Study Using Resting-State Functional Magnetic Resonance Imaging

    Guo Y, Zhang Z, Chen B et al. · Journal of integrative neuroscience · 2026

  22. 0.87

    Long-Term Effect of Acetylcholinesterase Inhibitors on Behavioral and Psychological Symptoms of Dementia

    Zuliani G, Boscolo Bragadin F, Romagnoli T et al. · International journal of geriatric psychiatry · 2026

  23. 0.86

    Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction

    Shahim B, Xu H, Haugaa K et al. · European heart journal. Cardiovascular pharmacotherapy · 2024

  24. 0.86

    A 52-week, open-label, observational study evaluating tolerability, efficacy and physicians satisfaction of rivastigmine oral solution in Alzheimer's disease in Taiwan

    Lee CY, Wang WF, Hsu JL et al. · Journal of Alzheimer's disease reports · 2025

  25. 0.86

    A causal inference study: The impact of the combined administration of Donepezil and Memantine on decreasing hospital and emergency department visits of Alzheimer's disease patients

    Yaghmaei E, Pierce A, Lu H et al. · PloS one · 2023

  26. 0.85

    Discontinuation of Cholinesterase Inhibitors Following Initiation of Memantine and Admission to Long-Term Care Among Older Adults

    Lee YC, Shi SM, Sison SM et al. · JAMA network open · 2024

  27. 0.84

    Relationship between the response to donepezil and plasma amyloid beta oligomers in patients with Alzheimer's disease

    Yang Y, Huh K, Kwak YT · Geriatrics & gerontology international · 2024

  28. 0.84

    White matter hyperintensities in cholinergic pathways may predict poorer responsiveness to acetylcholinesterase inhibitor treatment for Alzheimer's disease

    Lee LH, Wu SC, Ho CF et al. · PloS one · 2023

  29. 0.84

    Treatment persistence with acetylcholinesterase inhibitors in Alzheimer's disease: Real-world evidence from a retrospective cohort study

    Ho BL, Liu CF, Huang YB et al. · Journal of Alzheimer's disease : JAD · 2026

  30. 0.84

    Memantine in the treatment of dementia: a nationwide real-world analysis

    Halmos PM, Dobi B, Vinnai P et al. · GeroScience · 2026

  31. 0.83

    Donepezil-associated survival benefits among Alzheimer's disease patients are retained but not enhanced during COVID-19 infections

    Edmiston EA, Bej TA, Wilson B et al. · Therapeutic advances in infectious disease · 2023

  32. 0.83

    Real-world assessment of caregiver preference and compliance to treatment with twice-weekly versus daily rivastigmine patches in Alzheimer's disease

    Garcia-Alberca JM, De La Guia P, Gris E et al. · Journal of Alzheimer's disease : JAD · 2024

  33. 0.82

    Efficacy of donepezil combined with rehabilitation training in the treatment of Alzheimer's disease

    Yi Y, Deng X · Pakistan journal of medical sciences · 2025

  34. 0.82

    Early intervention and adding effective doses of EGb761 like Ginkgo extract slow down dementia progression: insights to the neurovascular unit

    Ozge A, Ghouri R, Oksuz N et al. · Frontiers in neurology · 2023

  35. 0.82

    Hospitalization for Malignant Arrhythmias Following Initiation of Donepezil: A Retrospective Cohort Study

    Huang Y, Gamble JM, Juurlink DN et al. · Pharmacoepidemiology and drug safety · 2026

  36. 0.81

    Treatment Effects of Cholinesterase Inhibitors in Alzheimer's Disease: a Causal Machine Learning Approach

    Dedebant E, Even M, Tornqvist M et al. · medRxiv : the preprint server for health sciences · 2026

  37. 0.81

    Safety issues of Donepezil combined with Memantine in Alzheimer's disease population: real-world pharmacovigilance

    Zeng Y, Liu B, Zhou L et al. · Expert opinion on drug safety · 2026

  38. 0.81

    The impact of CYP2D6 on donepezil concentration and its lack of effect on the treatment response and adverse effect in Korean patients with Alzheimer's disease

    Kim TE, Bae JW, Hong S et al. · The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025

  39. 0.81

    Moderation of Amyloid-beta Deposition on the Effect of Cholinesterase Inhibitors on Cognition in Mild Cognitive Impairment

    Byeon G, Byun MS, Yi D et al. · Journal of Alzheimer's disease : JAD · 2024

  40. 0.81

    The impact of cholinesterase inhibitors on cognitive trajectories in mild cognitive impairment patients based on amyloid beta status

    Liu W, Li Y, Qin W et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

  41. 0.80

    Predicting the efficacy of donepezil intervention in Alzheimer's disease patients using regional homogeneity in the inferior orbitofrontal cortex

    Dai M, Guo Z, Xia H et al. · Aging clinical and experimental research · 2024

  42. 0.80

    Citicoline: A Cholinergic Precursor with a Pivotal Role in Dementia and Alzheimer's Disease

    Gareri P, Cotroneo AM, Montella R et al. · Journal of Alzheimer's disease : JAD · 2024

  43. 0.80

    Increased Hippocampal-Inferior Temporal Gyrus White Matter Connectivity following Donepezil Treatment in Patients with Early Alzheimer's Disease: A Diffusion Tensor Probabilistic Tractography Study

    Kim GW, Park K, Kim YH et al. · Journal of clinical medicine · 2023

  44. 0.79

    Extemporaneous combination of donepezil and memantine to treat dementia in Alzheimer disease: evidence from Italian real-world data

    Padovani A, Falato S, Pegoraro V · Current medical research and opinion · 2023

  45. 0.79

    Comparative risk of ventricular arrhythmia and sudden cardiac death among acetylcholinesterase inhibitors in dementia: A population-based cohort study

    Lai HY, Meng LC, Ye YJ et al. · British journal of clinical pharmacology · 2026

  46. 0.78

    Efficacy of Souvenaid(R) Combined with Acetylcholinesterase Inhibitors in the Treatment of Mild Alzheimer's Disease

    Garcia-Alberca JM, Gris E, de la Guia P et al. · Journal of Alzheimer's disease : JAD · 2023

  47. 0.78

    Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized controlled and open-label observation trial

    Lee W, Kim M · Medicine · 2024

  48. 0.77

    Adverse events of Alzheimer's disease patients treated with memantine-based therapies: A disproportionality analysis of the FAERS database based on the MY FAERS platform

    Wang X, Zhang W, He J et al. · Journal of Alzheimer's disease : JAD · 2026

  49. 0.76

    Speech-related parameters are sensitive measures of acetylcholinesterase inhibitor therapy in mild Alzheimer's disease

    Hegedus E, Pakaski M, Gosztolya G et al. · PloS one · 2024

  50. 0.76

    Patterns, determinants, and outcomes of early use of antidementia drugs: A 6-year multicenter cohort study in Thailand

    Phatthanasobhon S, Singkham N, Na-Ek N et al. · Archives of gerontology and geriatrics · 2025

  51. 0.76

    Efficacy of donepezil plus hydrogen-oxygen mixture inhalation for treatment of patients with Alzheimer disease: A retrospective study

    Dan Z, Li H, Xie J · Medicine · 2023

  52. 0.76

    Cholinesterase inhibitor use in amyloid PET-negative mild cognitive impairment and cognitive changes

    Pyun JM, Park YH, Kang MJ et al. · Alzheimer's research & therapy · 2024

  53. 0.76

    Switching from Oral Cholinesterase Inhibitors to a Transdermal Donepezil Patch Attenuated Gastrointestinal Symptoms and Allowed Treatment Continuation in Three Patients with Alzheimer's Disease in Clinical Settings

    Motoi Y, Sanjo N · Brain sciences · 2026

  54. 0.76

    Caregiver-Reported Behavioral Changes After Donepezil Transdermal Patch Therapy in Alzheimer's Disease: An Exploratory Real-World Network Analysis

    Shimazu T, Hoshino E, Nakaseko M et al. · Neuropsychiatric disease and treatment · 2026

  55. 0.76

    Drug Response of Iranian Alzheimer's Patients to Rivastigmine Concerning Their Genotype for VDR rs11568820 and MTHFR C677T Variants: A Pharmacogenetic and Association Study

    Rizi ZS, Shams L, Rad FR et al. · Journal of molecular neuroscience : MN · 2024

  56. 0.76

    Efficacy of Acetylcholinesterase Inhibitors in the Logopenic Variant of Primary Progressive Aphasia

    Carrier-Auclair J, Lavoie M, Tastevin M et al. · Dementia and geriatric cognitive disorders · 2025

  57. 0.75

    Alzheimer's disease and memantine effects on NMDA-receptor blockade: non-invasive in vivo insights from magnetoencephalography

    Lanskey JH, Jafarian A, Hughes LE et al. · Molecular psychiatry · 2026

  58. 0.75

    Healthcare related costs associated with donepezil use in patients with very mild dementia due to Alzheimer's disease: A retrospective observational study

    Hsieh SW, Hsiao CY, Yang YH et al. · Journal of Alzheimer's disease reports · 2025

  59. 0.75

    Translating clinical notes into quantitative measures-a real-world observation on the response to cholinesterase inhibitors or selective serotonin reuptake inhibitors prescribed to outpatients with dementia using electronic medical records

    Chotiyanonta JS, Onda K, Nowrangi MA et al. · Frontiers in pharmacology · 2023

  60. 0.75

    Discontinuation of Alzheimer Disease Medications in Patients Receiving Home Care Medicine

    Kidana K, Yamaga R, Fujii H et al. · Alzheimer disease and associated disorders · 2024

  61. 0.74

    Association of CHAT Gene Polymorphism rs3793790 and rs2177370 with Donepezil Response and the Risk of Alzheimer's Disease Continuum

    Sun H, Lv C, Zhang X et al. · Clinical interventions in aging · 2024

  62. 0.74

    Do cognitive and neurophysiological effects of acute memantine "challenge" predict its clinical benefits in Alzheimer's Disease?

    Swerdlow NR, Sprock J, Gonzalez CE et al. · Psychiatry research · 2025

  63. 0.74

    Association between Polypharmacy and Adverse Events in Patients with Alzheimer's Disease: An Analysis of the Japanese Adverse Drug Event Report Database (JADER)

    Otani N, Kanda K, Ngatu NR et al. · Medicina (Kaunas, Lithuania) · 2024

  64. 0.74

    Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure

    Reimers-Wessberg M, Xu H, Fastbom J et al. · European heart journal. Cardiovascular pharmacotherapy · 2025

  65. 0.73

    Combining Mini-Mental State Examination and Montreal Cognitive Assessment for assessing the clinical efficacy of cholinesterase inhibitors in mild Alzheimer's disease: a pilot study

    Furneri G, Varrasi S, Guerrera CS et al. · Aging clinical and experimental research · 2024

  66. 0.73

    Brain Age Is Associated with Cognitive Outcomes of Cholinesterase Inhibitor Treatment in Patients with Mild Cognitive Impairment

    Tseng WYI, Hsu YC, Huang LK et al. · Journal of Alzheimer's disease : JAD · 2024

  67. 0.72

    Falls and Fractures Among Medicare Beneficiaries Concurrently Receiving Anti-Dementia Drugs and Potentially Risky Medications

    Morden NE, Chyn D, Meara E · Medical care · 2025

  68. 0.72

    Association between cholinesterase inhibitors and kidney function decline in patients with Alzheimer's dementia

    Xu H, Garcia-Ptacek S, Bruchfeld A et al. · Kidney international · 2023

  69. 0.72

    Acetylcholinesterase inhibitors and the risk of delirium - a Danish nationwide register-based cohort study

    Rahbek MT, Kildegaard H, Hallas J et al. · Alzheimer's research & therapy · 2026

  70. 0.72

    Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer's disease: a target trial emulation

    Lee CY, Hsu CW, Tseng PT et al. · Alzheimer's research & therapy · 2026

  71. 0.72

    Fractional amplitude of low-frequency fluctuations in right dorsal cingulum bundle associated with depression symptoms in AD patients: effects of donepezil intervention

    Guo Z, Wei F, Hou H et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025

  72. 0.72

    A comprehensive assessment of cholinesterase inhibitors for the treatment of Alzheimer's disease based on drug selection recommendations for Chinese medical institutions

    Lv J, Cai X, Yang Z et al. · Expert review of pharmacoeconomics & outcomes research · 2026

  73. 0.72

    A phase 1, safety, tolerability, and pharmacokinetics study of bisnorcymserine, a highly selective inhibitor of butyrylcholinesterase

    Tzieras I, Manolopoulos A, Tweedie D et al. · Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026

  74. 0.71

    Efficacy and safety of Woohwangchungsimwon in combination with donepezil for behavioral and psychological symptoms of dementia in probable Alzheimer's disease: An assessor-blinded randomized controlled trial

    Kim MG, Woo SH, Kim GW et al. · Journal of Alzheimer's disease : JAD · 2026

  75. 0.71

    Cumulative Anticholinergic Burden and Risk of Delirium Among Older Adults with Alzheimer's Disease

    Talwar A, Sherer J, Abughosh S et al. · Pharmacy (Basel, Switzerland) · 2026

  76. 0.71

    Clinical observation on treatment of Alzheimer's disease with Sun's scalp-abdominal acupuncture combined with donepezil hydrochloride

    Zhang SQ, Ma S, Yang TS et al. · Zhen ci yan jiu = Acupuncture research · 2024

  77. 0.71

    Causal effect of conventional anti-dementia drugs on economic burden: an orthogonal double/debiased machine learning approach

    Jiang X, Lv G, Franklin J et al. · BMC geriatrics · 2025

  78. 0.70

    Brain morphological characteristics predicting clinical response to selective serotonin reuptake inhibitors or cholinesterase inhibitors: A study of electronic medical records in patients with cognitive disorders

    Onda K, Chotiyanonta JS, Cowley HP et al. · International psychogeriatrics · 2025

  79. 0.70

    Comprehensive safety assessment of donepezil: pharmacovigilance analysis based on the FDA adverse event reporting system

    Li S, Qian W, Zhang Z et al. · Frontiers in neurology · 2025

  80. 0.70

    Clinicians' Perspectives of Twice-Weekly Rivastigmine Patches for Alzheimer's Disease Treatment in Spain: The VIITAL 2S Study

    Pinol-Ripoll G, Salas Carrillo M · Patient preference and adherence · 2025

  81. 0.70

    Investigation of the gait parameters after donepezil treatment in patients with alzheimer' s disease

    Bizpinar O, Onder H · Applied neuropsychology. Adult · 2025

  82. 0.69

    Changes in dementia treatment patterns associated with changes in the National Policy in South Korea among patients with newly diagnosed Alzheimer's disease between 2011 and 2017: results from the multicenter, retrospective CAPTAIN study

    Kim YJ, So KY, Lee HM et al. · BMC public health · 2024

  83. 0.69

    Effects of pressing moxibustion at Baihui (GV 20) and Guanyuan (CV 4) on cognitive impairment and serum levels of Abeta(1-42), tau, P-tau in patients with mild to moderate Alzheimer's disease

    Yang S, Fan D, Su S et al. · Zhongguo zhen jiu = Chinese acupuncture & moxibustion · 2024

  84. 0.68

    Risk of antimuscarinic initiation with cholinesterase inhibitor use in Alzheimer's disease

    Chikermane SG, Li J, Aparasu RR · Archives of gerontology and geriatrics · 2025

  85. 0.68

    Effects of Cholinesterase Inhibitor Medication on QTc Interval in Memory Clinic Patients

    Isotalo HK, Lehtovaara JK, Ekblad LL et al. · The Annals of pharmacotherapy · 2026

  86. 0.68

    Variants in Neurotransmitter-Related Genes Are Associated with Alzheimer's Disease Risk and Cognitive Functioning but Not Short-Term Treatment Response

    Zuniga-Santamaria T, Perez-Aldana BE, Fricke-Galindo I et al. · Neurology international · 2025

  87. 0.67

    Characterizing Treatment Non-responders and Responders in Completed Alzheimer's Disease Clinical Trials

    Wang D, Ling Y, Harris K et al. · AMIA ... Annual Symposium proceedings. AMIA Symposium · 2024

  88. 0.67

    Preliminary Evidence that Memantine Enhances Prepulse Effects on Startle Magnitude and Latency in Patients with Alzheimer's Disease

    Swerdlow NR, Joshi YB, Sprock J et al. · Journal of Alzheimer's disease : JAD · 2023

  89. 0.67

    Donepezil increases angiogenic potential in patients with Alzheimer's disease

    Lee M, Kim M · Journal of Alzheimer's disease : JAD · 2026

  90. 0.67

    Safety Comparison of Acetylcholinesterase Inhibitors Using FAERS Spontaneous-Reporting Data: Drug-Specific Reporting Signals and Time-to-Onset Dynamics

    Du Y, Li J, Han F et al. · Current Alzheimer research · 2026

  91. 0.67

    Patterns of use of symptomatic treatments for Alzheimer's disease dementia (AD)

    DiBello JR, Lu Y, Swartz J et al. · BMC neurology · 2023

  92. 0.67

    Treatment Duration of Cholinesterase Inhibitor Formulations in Alzheimer's Disease

    Sato S, Sasabuchi Y, Yamana H et al. · Journal of the American Medical Directors Association · 2026

  93. 0.66

    Enhancing Outcomes in Alzheimer's Disease: Exploring the Effects of a Diversified Rehabilitation Program Combined with Donepezil on Apathy, Cognitive Function, and Family Caregiver Burden

    Ji X, Liang L · Actas espanolas de psiquiatria · 2024

  94. 0.66

    Examining the impact of Anticholinergic Burden on Hospitalized Older People Receiving Concomitant Cholinesterase inhibitors

    Guan J, Noviasky J, Watanabe JH · The Senior care pharmacist · 2024

  95. 0.65

    Impact of modifications to antidementia drug reimbursement in France: Analysis of the FRA-DEM cohort

    Couret A, Gardette V, Renoux A et al. · British journal of clinical pharmacology · 2024

  96. 0.65

    Antidementia Medication Use in Nursing Home Residents

    Ott BR, Hollins C, Tjia J et al. · Journal of geriatric psychiatry and neurology · 2024

  97. 0.64

    Prescribing of anti-dementia medications in primary care: A retrospective cohort study in 1489 English General Practices

    Morris C, Mok PLH, Robinson DL et al. · PloS one · 2026

  98. 0.64

    Characterizing Treatment Non-responders vs. Responders in Completed Alzheimer's Disease Clinical Trials

    Wang D, Ling Y, Harris K et al. · medRxiv : the preprint server for health sciences · 2023

  99. 0.63

    Cumulative Anticholinergic Burden and its Predictors among Older Adults with Alzheimer's Disease Initiating Cholinesterase Inhibitors

    Talwar A, Chatterjee S, Sherer J et al. · Drugs & aging · 2024

  100. 0.62

    Effect of Social Isolation Due to the COVID-19 Pandemic on Cognitive Dysfunction of Patients With Alzheimer Disease: Subanalysis of Double-blinded Noninferiority Study of Donepezil Patches and Donepezil Tablets

    Nakamura Y, Omori T, Nishiyama K et al. · Alzheimer disease and associated disorders · 2024

  101. 0.62

    A regional registry ensures clinical guideline adherence and economic sustainability of Alzheimer's disease treatment: a 12-year population-based study in Catalonia

    Umbria M, Exposito J, Gasol M et al. · Frontiers in pharmacology · 2026

  102. 0.62

    Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study

    Dangpiaei S, Kamal KM, Shoair OA et al. · Journal of managed care & specialty pharmacy · 2026

  103. 0.61

    Evaluating the Cost-Effectiveness of Pharmacological Therapy in Alzheimer Disease in Brazil

    Price PU, Heggie R, Moriguti JC et al. · Value in health regional issues · 2025

  104. 0.61

    The value of cholinesterase inhibitors for improving neuropsychiatric and functional assessment scores in patients with Alzheimer disease: a systematic review and meta-analysis of on placebo-controlled RCTs

    Zhang Y, Sun Y, Hu X et al. · International journal of surgery (London, England) · 2024

  105. 0.61

    Treatment patterns of symptomatic treatments for Alzheimer's disease and related dementias

    Deng H, Lee TA, Gaber CE et al. · BMC geriatrics · 2025

  106. 0.60

    Efficacy and predictors of cognitive stimulation therapy combined with pharmacotherapy for mild-to-moderate Alzheimer's disease: a randomized controlled trial

    Cai L, Zhao X, Liao C et al. · Frontiers in psychiatry · 2026

  107. 0.60

    Bioequivalence of a Donepezil/Memantine 10/20 mg Fixed-Dose Combination Versus Single-Component Tablets in Healthy Korean Males

    Choi M, Jin BH, Keum DH et al. · Clinical pharmacology in drug development · 2025

  108. 0.60

    Medications and cognitive decline in Alzheimer's disease: Cohort cluster analysis of 15,428 patients

    Grau-Jurado P, Mostafaei S, Xu H et al. · Journal of Alzheimer's disease : JAD · 2025

  109. 0.60

    Effects of Combined Intervention of rTMS and Neurotransmitter Drugs on the Brain Functional Networks in Patients with Cognitive Impairment

    Li M, Qin Z, Chen H et al. · Brain sciences · 2023

  110. 0.60

    Potential Cardiologic Protective Effects of Acetylcholinesterase Inhibitors in Patients With Mild to Moderate Dementia

    Rampa L, Santangelo R, Gaspardone C et al. · The American journal of cardiology · 2023

  111. 0.60

    Prescribing memantine in general practice in England: a mixed-methods study

    Carter M, Butterworth J, Fox C et al. · BJGP open · 2025

  112. 0.60

    Effect of Social Restriction Due to the COVID-19 Pandemic on Activity of Daily Living and Disease Severity of Patients With Alzheimer Disease: Sub-analysis of a Double-blinded Noninferiority Study of Donepezil Patches and Donepezil Tablets

    Nakamura Y, Omori T, Nishiyama K et al. · Alzheimer disease and associated disorders · 2025

  113. 0.59

    Altered Effective Connectivity Within the Frontoparietal Network in Alzheimer's Disease and Its Modulation by Acupuncture: A Resting-State fMRI Study

    Wei YT, Li L, Xie WT et al. · Neuropsychiatric disease and treatment · 2026

  114. 0.59

    Identification of profiles associated with conversions between the Alzheimer's disease stages, using a machine learning approach

    Dauphinot V, Laurent M, Prodel M et al. · Alzheimer's research & therapy · 2024

  115. 0.59

    A comprehensive German claims data analysis of care pathways, risk factors and comorbidities among acetylcholinesterase inhibitor initiators in Alzheimer's disease

    Maas C, Fang L, Mathey E et al. · Scientific reports · 2026

  116. 0.59

    Does concurrent pharmacotherapy enhance behavioral interventions for mild cognitive impairment? Evidence from the HABIT program

    Xie Z, Locke D, Shandera-Ochsner A et al. · Journal of Alzheimer's disease : JAD · 2026

  117. 0.58

    Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial

    Dubois B, Lopez-Arrieta J, Lipschitz S et al. · Alzheimer's research & therapy · 2023

  118. 0.58

    Effects of rivastigmine on gait in patients with neurodegenerative disorders: A systematic review and meta-analysis

    Shim SR, Kim JY, Kwon KY et al. · PloS one · 2024

  119. 0.58

    An overview of the rivastigmine 13.3 mg/24h transdermal patch as a treatment option for Alzheimer's disease

    Fortea J, Ferrer-Picon E · Expert review of neurotherapeutics · 2025

  120. 0.57

    Evaluating the efficacy and safety of Alzheimer's disease drugs: A meta-analysis and systematic review

    Chen Y, Lai M, Tao M · Medicine · 2024

  121. 0.57

    Effect of donepezil on bone metabolism among older adults with Alzheimer's disease

    North R, Liu AJ, Pieper C et al. · Contemporary clinical trials · 2025

  122. 0.56

    Using artificial intelligence to learn optimal regimen plan for Alzheimer's disease

    Bhattarai K, Rajaganapathy S, Das T et al. · Journal of the American Medical Informatics Association : JAMIA · 2023

  123. 0.56

    Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact

    Olazaran J, Carnero-Pardo C, Fortea J et al. · Alzheimer's research & therapy · 2023

  124. 0.55

    Caregiver burden, not patient cognitive impairment, predicts adherence to donepezil transdermal patch in Alzheimer's disease: A retrospective real-world study

    Yajima R, Ishiguro T, Michikawa M et al. · Journal of Alzheimer's disease reports · 2026

  125. 0.55

    Acupuncture as an adjunct therapy for mild Alzheimer's disease: A randomized clinical trial

    Kong X, Han R, Fan X et al. · Journal of Alzheimer's disease : JAD · 2026

  126. 0.55

    Anti-dementia drugs: a descriptive study of the prescription pattern in Italy

    Ippoliti I, Ancidoni A, Da Cas R et al. · Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023

  127. 0.54

    Cholinesterase inhibitors for patients with dementia: Patterns of prescribing and disparities in treatment

    Heo RJ, Negida A, Barrett MJ et al. · Journal of Alzheimer's disease : JAD · 2026

  128. 0.53

    Safety, tolerability, and pharmacokinetics of fluoropezil (DC20), a novel acetylcholinesterase inhibitor: A phase I study in healthy young and elderly Chinese subjects

    Qian H, Yu C, Zhu H et al. · Clinical and translational science · 2023

  129. 0.53

    Evaluating the safety of investigational anti-Alzheimer's drugs: a comprehensive meta-analysis in the past to current decade

    Shaik NS, Balya H, Ramamurthy S et al. · Dementia & neuropsychologia · 2026

  130. 0.53

    Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI

    Leijenaar JF, Ingala S, Sudre CH et al. · Cerebral circulation - cognition and behavior · 2022

  131. 0.53

    The role of ethnicity, biological sex, and psychotropic agents in early and late onset Alzheimer's disease

    Miller A, Desai A, Roley LT et al. · Frontiers in aging neuroscience · 2022

  132. 0.52

    Adherence of Anti-Dementia Medications in Alzheimer's Disease and Related Dementia: A Nationwide Cohort Study in Korea

    Lee E, Kang S, Ye BS et al. · Journal of Korean medical science · 2025

  133. 0.52

    Medication prescriptions among patients with mild cognitive impairment and Alzheimer's disease: A large nationwide electronic health record cohort study

    Boroje I, Sanchez-Solino O, Yue EX et al. · Journal of Alzheimer's disease : JAD · 2025

  134. 0.52

    Annual Wellness Visits and New Dementia Medication Prescriptions Among US Medicare Beneficiaries

    Milani SA, Kuo YF, Shan Y et al. · JAMA network open · 2026

  135. 0.52

    Dementia medications and the use of psychotropic drugs: A cross-sectional study in Saudi healthcare

    Hajjar SH, Alamri SH, AlFouzan MA et al. · Journal of Alzheimer's disease : JAD · 2026

  136. 0.52

    Examining pharmacological and demographic factors among male and female alzheimer's disease patients diagnosed with attention concentration disorder and cognitive communication disorder

    Desai A, Agbomi LL, Nathaniel AI et al. · Geriatric nursing (New York, N.Y.) · 2026

  137. 0.52

    Proarrhythmic major adverse cardiac events with donepezil: A systematic review with meta-analysis

    Nham T, Garcia MC, Tsang KLJ et al. · Journal of the American Geriatrics Society · 2024

  138. 0.51

    Indian Psychiatric Society multicentre study: Diagnostic patterns, comorbidity and prescription practices for patients with Dementia

    Kumar CS, Varghese M, Duddu V et al. · Indian journal of psychiatry · 2023

  139. 0.51

    Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis

    Bittner N, Funk CSM, Schmidt A et al. · Drugs & aging · 2023

  140. 0.51

    Comparative efficacy and safety of pathway-targeted pharmacotherapies for Alzheimer's disease: A systematic review and network meta-analysis of phase III trials

    Wu Y, Di Y, Wang H et al. · Ageing research reviews · 2026

  141. 0.51

    Uptake and safety profile of anti-amyloid immunotherapies in routine clinical practice

    Lusk JB, Fitch KV, Johnson KG et al. · Journal of Alzheimer's disease reports · 2026

  142. 0.50

    Dementia Medications and Their Association with Pain Medication Use in Medicare Beneficiaries with Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Chronic Pain

    Milani SA, Westra J, Kuo YF et al. · Drugs & aging · 2025

  143. 0.50

    Real-World Use of Symptomatic Treatments in Early Alzheimer's Disease

    Garcia MJ, Leadley R, Lang S et al. · Journal of Alzheimer's disease : JAD · 2023

  144. 0.50

    Geographic Variation of Antidementia and Antipsychotic Medication Use Among US Nursing Home Residents With Dementia

    Rataj A, Alcusky M, Baek J et al. · Medical care · 2024

02rats · oxidative stress30편

  1. 0.75

    Serum Cytokine 6, 10 and alpha-Tumour Necrosis Factor Levels in Alzheimer's Disease Subjects Treated with Donepezil Plus Vitamin B12

    Yeram N, Dalvi SM, Kale VP et al. · Neurology India · 2025

  2. 0.73

    Effect of metformin on anti-Alzheimer activity of rivastigmine in aluminum chloride-induced Alzheimer's disease in rats: A behavioral, biochemical, immunohistopathological evidence of crosstalk between amyloid, tau, autophagy, and apoptosis

    Abdel-Aal RA, Abdelnabi S, Badary DM et al. · European journal of pharmacology · 2026

  3. 0.72

    Differential cognitive enhancer effects of acetylcholinesterase inhibitors and memantine on age-related deficits in vigilance and sustained attention: a preclinical validation study

    Bali ZK, Bruszt N, Gonter K et al. · Behavioral and brain functions : BBF · 2025

  4. 0.69

    To evaluate the effect of endothelin receptor agonist IRL-1620 alone and in combination with donepezil in modulating neurodegeneration elicited by amyloid-beta in rats

    Mahajan E, Raja A, Sharma AR et al. · Experimental neurology · 2024

  5. 0.67

    Potential therapeutic effects of Ebixa, Ginkgo biloba, and selenium in a cadmium chloride-induced Alzheimer's disease manifestations in rats

    Alrikabi A, Allahyani W, Shaghath A et al. · Frontiers in neuroscience · 2025

  6. 0.65

    Comparing levetiracetam and zonisamide effects on rivastigmine anti-Alzheimer's activity in aluminum chloride-induced Alzheimer's-like disease in rats: Impact on alpha7 nicotinic acetylcholine receptors and amyloid beta

    Abdel-Aal RA, Meligy FY, Maghraby N et al. · Brain research · 2025

  7. 0.65

    Neuroprotective Effect of Quercetin and Memantine against AlCl(3)-Induced Neurotoxicity in Albino Wistar Rats

    Jadhav R, Kulkarni YA · Molecules (Basel, Switzerland) · 2023

  8. 0.64

    Neuroprotective Effects of Liraglutide and/or Rivastigmine Combination on the Rat Hippocampus

    Abdel-Aal RA, Hareedy MS, Badary DM et al. · Drug development research · 2025

  9. 0.64

    The Combination of Baicalein and Memantine Reduces Oxidative Stress and Protects against beta-amyloid-Induced Alzheimer's Disease in Rat Model

    Jadhav R, Kulkarni YA · Antioxidants (Basel, Switzerland) · 2023

  10. 0.63

    The involvement of neuroinflammation in an animal model of dementia and depression

    Zabot GC, Medeiros EB, Macarini BMN et al. · Progress in neuro-psychopharmacology & biological psychiatry · 2024

  11. 0.63

    Effects of hydromethylthionine mesylate and rivastigmine in a pharmacological mouse model of Alzheimer's disease

    Robinson L, Bray J, Melis V et al. · Behavioural pharmacology · 2026

  12. 0.61

    Effects of baicalein with memantine on aluminium chloride-induced neurotoxicity in Wistar rats

    Jadhav R, Kulkarni YA · Frontiers in pharmacology · 2023

  13. 0.60

    Comparative Effects of Donepezil and Tacrine on Recall-Related Exploratory Behavior in a Subacute Lipopolysaccharide-Induced Neuroinflammatory Model of Cognitive Impairment

    Dragomir AF, Barbu AC, Stoleru S et al. · Biomedicines · 2026

  14. 0.57

    Effects of donepezil treatment on plasma and urine metabolites in amyloid beta-induced Alzheimer's disease rats

    Huang H, Fang C, Niu H et al. · Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2023

  15. 0.57

    Crocin Mitigates Glutamate Excitotoxicity and Tau Hyperphosphorylation by Modulating EAAT2 and Akt/Tau Pathway in a Scopolamine-induced Rat Model of Alzheimer's Disease

    El-Baga SE, Hassan MH, Awadalla EA et al. · Neurochemical research · 2026

  16. 0.57

    Synergistic Effect of Donepezil and Neurotropic B Vitamins on Dysregulated Antioxidant, Inflammation and Neurotransmitter Status in Aluminium Chloride-Induced Neurotoxicity in Rats

    Ekundayo BE, Adewale OB, Obafemi BA et al. · Cell biochemistry and function · 2024

  17. 0.56

    Empagliflozin and memantine combination ameliorates cognitive impairment in scopolamine + heavy metal mixture-induced Alzheimer's disease in rats: role of AMPK/mTOR, BDNF, BACE-1, neuroinflammation, and oxidative stress

    Abdel-Lah ES, Sherkawy HS, Mohamed WH et al. · Inflammopharmacology · 2025

  18. 0.56

    Comparison of the effect of donepezil and a combination of donepezil and mefloquine (THN201) on cognition during a scopolamine challenge in healthy participants

    Dondaine T, Rein W, Micallef J et al. · Experimental and clinical psychopharmacology · 2026

  19. 0.55

    Edaravone Improves Streptozotocin-Induced Memory Impairment via Alleviation of Behavioral Dysfunction, Oxidative Stress, Inflammation, and Histopathological Parameters

    Anoush M, Bijani S, Moslemifar F et al. · Behavioural neurology · 2023

  20. 0.55

    Evaluation of the Neurotherapeutic Effect of Quercetin on Neuronal miR-124 and beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) in an Experimental Alzheimer's Disease Model

    Al-Sawasany AS, Fayed HM, Mahmoud BF et al. · Journal of biochemical and molecular toxicology · 2025

  21. 0.53

    Metabolic Activation and Cytotoxicity of Donepezil Induced by CYP3A4

    Zheng J, Zhao G, Hu Z et al. · Chemical research in toxicology · 2024

  22. 0.53

    Comparative Study of the Effect of Liraglutide and Donepezil on Learning and Memory in Diazepam-Induced Amnesic Albino Rats

    Kumari K, Kumar S, Sinha RK et al. · Cureus · 2023

  23. 0.53

    Effects of thymoquinone and memantine alone and in combination on memory and hippocampal morphology in rats with streptozotocin-induced Alzheimer's disease

    Ozsoy S, Cakir Z, Akcay E et al. · Turkish journal of medical sciences · 2023

  24. 0.52

    Homocysteine decreases VEGF, EGF, and TrkB levels and increases CCL5/RANTES in the hippocampus: Neuroprotective effects of rivastigmine and ibuprofen

    Ramires Junior OV, Silveira JS, Gusso D et al. · Chemico-biological interactions · 2024

  25. 0.52

    Ameliorative effects of bromelain on aluminum-induced Alzheimer's disease in rats through modulation of TXNIP pathway

    Eraky SM, Ramadan NM, Abo El-Magd NF · International journal of biological macromolecules · 2023

  26. 0.51

    Donepezil-loaded PLGA-b-PEG Nanoparticles Enhance the Learning and Memory Function of Beta-Amyloid Rat Model of Alzheimer's Disease

    Cinar E, Mutluay SU, Baysal I et al. · Noro psikiyatri arsivi · 2022

  27. 0.50

    Magnoflorine-Loaded Chitosan Collagen Nanocapsules Ameliorate Cognitive Deficit in Scopolamine-Induced Alzheimer's Disease-like Conditions in a Rat Model by Downregulating IL-1beta, IL-6, TNF-alpha, and Oxidative Stress and Upregulating Brain-Derived Neurotrophic Factor and DCX Expressions

    Bashir DJ, Manzoor S, Sarfaraj M et al. · ACS omega · 2023

  28. 0.50

    Neuroprotective Effect of Empagliflozin/Rivastigmine in Alzheimer's Disease Rat Model: Optimization of Multifaceted Mechanism of Action

    Abdel-Lah ES, Hamad N, Taha AF et al. · Drug development research · 2025

  29. 0.50

    Ameliorative anti-coagulant, anti-oxidative and anti-ferroptotic activities of nanocurcumin and donepezil on coagulation, oxidation and ferroptosis in Alzheimer's disease

    Nawar NF, Beltagy DM, Mohamed TM et al. · Toxicology research · 2024

  30. 0.50

    Reveal the mechanism of action of donepezil combined with nimodipine in the treatment of Alzheimer's disease via metabolomics and lipidomics analyses in rats

    Ji Y, Cui X, Ding Z et al. · Journal of Alzheimer's disease : JAD · 2026

03mice · expression24편

  1. 0.79

    Memantine Administration Enhances Glutamatergic and GABAergic Pathways in the Human Hippocampus of Alzheimer's Disease Patients

    Fabrik I, Kupcik R, Fabrikova D et al. · Proteomics · 2025

  2. 0.75

    Combined Preventive and Preconditioning Treatments for the Comorbidity of Alzheimer's Disease and Ischemic Stroke in a GluN3A Knockout Mouse and a 5xFAD Mouse

    Yu SP, Gu X, Jiang MQ et al. · Cells · 2025

  3. 0.73

    Efficacy evaluation and metabolomics analysis of Huanglian Jiedu decoction in combination with donepezil for Alzheimer's disease treatment

    Xu M, Yue Y, Huang J · Journal of pharmaceutical and biomedical analysis · 2023

  4. 0.72

    In Vivo Evaluation of Nose-to-Brain Delivery of Liposomal Donepezil, Memantine, and BACE-1 siRNA for Alzheimer's Disease Therapy

    Lee D, Shen AM, Shah M et al. · International journal of molecular sciences · 2024

  5. 0.71

    From gut to brain: donepezil and nimodipine combination therapy improves cognitive deficits in Alzheimer's disease via gut microbiota and metabolites

    Liu J, Liu K, Cui X et al. · Biochemical and biophysical research communications · 2025

  6. 0.67

    State-Dependent Alterations of Hippocampal Theta-Gamma Coupling in 5xFAD Mice and Their Differential Modulation by Donepezil

    Wang H, Wang Y, Lv Z et al. · Brain sciences · 2026

  7. 0.67

    Effect of Cerebralcare Granule(R) combined with memantine on Alzheimer's disease

    Yang M, Zhang X, Qiao O et al. · Journal of ethnopharmacology · 2024

  8. 0.67

    Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice

    Kondak C, Leith M, Baddeley TC et al. · International journal of molecular sciences · 2023

  9. 0.66

    Disease-modifying effect of donepezil on APP/PS1 mice at different stages of Alzheimer's disease

    Zueva I, Belyaev G, Petrov K · Molecular and cellular biochemistry · 2025

  10. 0.65

    Impact of Donepezil Supplementation on Alzheimer's Disease-like Pathology and Gut Microbiome in APP/PS1 Mice

    Li Y, Wu M, Kong M et al. · Microorganisms · 2023

  11. 0.62

    Folic acid as a potential therapeutic agent for Alzheimer's disease: Effects on inflammatory cytokines, amyloid deposition, and neurotransmitter metabolism

    Jing S, Wang Y, Liu Y et al. · Journal of medical biochemistry · 2025

  12. 0.62

    Hydromethylthionine rescues synaptic SNARE proteins in a mouse model of tauopathies: Interference by cholinesterase inhibitors

    Schwab K, Lauer D, Magbagbeolu M et al. · Brain research bulletin · 2024

  13. 0.61

    Effect of donepezil hydrochloride on the transgenic Drosophila expressing human Abeta-42

    Siddique YH, Naz F, Rahul et al. · The International journal of neuroscience · 2024

  14. 0.61

    Preventive Memantine Treatment at the Preclinical Stage in the Alzheimer's Disease Model of the 5xFAD Mouse

    Gu X, Yu SP, Jiang MQ et al. · Neuroscience bulletin · 2026

  15. 0.60

    Effect of woohwangchungsimwon and donepezil co-treatment on cognitive function and serum metabolic profiles in a scopolamine-induced model of Alzheimer's disease

    Kim JS, Kim MG, Ryu JE et al. · Journal of ethnopharmacology · 2024

  16. 0.58

    Age-dependent remodeling of the sciatic proteome in 5xFAD mice can be attenuated by exercise or donepezil treatment to maintain neuromuscular function

    Brisendine MH, Nieves-Esparcia DQ, Willoughby OS et al. · bioRxiv : the preprint server for biology · 2025

  17. 0.57

    Multi-functional memantine nitrate attenuated cognitive impairment in models of vascular dementia and Alzheimer's disease through neuroprotection and increased cerebral blood flow

    Chen G, Zhang K, Sun M et al. · Neuropharmacology · 2025

  18. 0.55

    Age-Dependent Remodeling of the Sciatic Nerve Proteome in 5xFAD Mice Can Be Attenuated by Exercise or Donepezil Treatment to Maintain Neuromuscular Function

    Brisendine MH, Nieves-Esparcia DQ, Willoughby OS et al. · Aging cell · 2026

  19. 0.54

    Changes in Dendritic Spine Density and Morphology during Therapy with Acetylcholinesterase Inhibitors in a Mouse Model of Alzheimer's Disease

    Belyaev GP, Petrov KA, Semenov VE et al. · Bulletin of experimental biology and medicine · 2025

  20. 0.53

    Combination strategy employing BACE1 inhibitor and memantine to boost cognitive benefits in Alzheimer's disease therapy

    Tarif AMM, Huhe H, Ohno M · Psychopharmacology · 2024

  21. 0.52

    Evaluation of microcurrent as an adjunct to donepezil therapy in an Alzheimer's disease mouse model: a pilot study

    Kim EH, Lee YJ, Moon YS et al. · Frontiers in aging neuroscience · 2025

  22. 0.52

    Rivastigmine interferes with the pharmacological activity of hydromethylthionine on presynaptic proteins in the line 66 model of frontotemporal dementia

    Schwab K, Robinson L, Annschuetz A et al. · Brain research bulletin · 2025

  23. 0.52

    Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer's-like Tauopathy Mouse Model

    Zadrozny M, Drapich P, Gasiorowska-Bien A et al. · Cells · 2024

  24. 0.51

    Fluoroethylnormemantine (FENM) shows synergistic protection in combination with a sigma-1 receptor agonist in a mouse model of Alzheimer's disease

    Freyssin A, Carles A, Guehairia S et al. · Neuropharmacology · 2024

04delivery · release22편

  1. 0.67

    Feasibility Study of Nose-to-Brain Delivery of Galantamine for Alzheimer's Disease: Enhancing Olfactory-Region Deposition to Improve Therapeutic Efficacy

    Chen C, Leung C, Zhai Z et al. · Pharmaceutics · 2026

  2. 0.66

    Modulation of experimental Alzheimer's disease in rats through donepezil-loaded CSF implant

    Osama L, ElShebiney S, Beherei HH et al. · Scientific reports · 2025

  3. 0.64

    ApoE3 Anchored Liposomal Delivery of Rivastigmine for Brain Delivery: Formulation, Characterization, and In Vivo Pharmacokinetic Evaluation

    Khairnar P, Singh A, Ahirwar K et al. · AAPS PharmSciTech · 2023

  4. 0.63

    Nose-to-brain delivery of donepezil within a small dose improves bioavailability and efficacy for Alzheimer's disease treatment

    Wang G, Duan X, Ouyang D et al. · Asian journal of pharmaceutical sciences · 2026

  5. 0.62

    A study of once-a-week donepezil transdermal system's bioequivalence to oral donepezil in healthy volunteers: a plain language summary

    Braeckman R, Oh C · Neurodegenerative disease management · 2023

  6. 0.58

    Implantable trilayer microneedle transdermal delivery system to enhance bioavailability and brain delivery of rivastigmine for Alzheimer treatment: A proof-of-concept study

    Ilyas NRA, Putri APD, Pratama FA et al. · European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2024

  7. 0.57

    The measured CSF/plasma donepezil concentration ratio but not individually measured CSF and plasma concentrations significantly increase over 24 h after donepezil treatment in patients with Alzheimer's disease

    Valis M, Dlabkova A, Hort J et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023

  8. 0.57

    A Preliminary Pharmacodynamic Study for the Management of Alzheimer's Disease Using Memantine-Loaded PLGA Nanoparticles

    Kaur A, Nigam K, Tyagi A et al. · AAPS PharmSciTech · 2022

  9. 0.56

    Pharmacokinetic Evaluation of GB-5001, a Long-Acting Injectable Formulation of Donepezil, in Healthy Korean Participants: Population Pharmacokinetics with Phase 1 Study

    Park YC, Seol E, Lee J et al. · Pharmaceutics · 2025

  10. 0.56

    Preparation and evaluation of injectable microsphere formulation for longer sustained release of donepezil

    Ji YB, Lee S, Ju HJ et al. · Journal of controlled release : official journal of the Controlled Release Society · 2023

  11. 0.55

    Pharmacokinetics and Bioavailability of a Novel Rivastigmine Nasal Spray Compared to Rivastigmine Oral Capsule in Healthy Men

    Morgan TM, Snyder B · Journal of clinical pharmacology · 2026

  12. 0.55

    Combined Donepezil with Astaxanthin via Nanostructured Lipid Carriers Effective Delivery to Brain for Alzheimer's Disease in Rat Model

    Shehata MK, Ismail AA, Kamel MA · International journal of nanomedicine · 2023

  13. 0.54

    Rivastigmine nasal spray for the treatment of Alzheimer's Disease: Olfactory deposition and brain delivery

    Guo H, Wang G, Zhai Z et al. · International journal of pharmaceutics · 2024

  14. 0.54

    Enhanced rivastigmine delivery through nanoemulsion and pyridoxine supplementation: An in-vivo study on Alzheimer's disease intervention

    Roy H, Maddiboyina B, Nandi S et al. · Nanomedicine : nanotechnology, biology, and medicine · 2025

  15. 0.53

    Valine conjugated polymeric nanocarriers for targeted co-delivery of rivastigmine and quercetin in rat model of Alzheimer disease

    Kaboli Z, Hosseini MJ, Sadighian S et al. · International journal of pharmaceutics · 2023

  16. 0.53

    Fabrication and characterization of dissolving microneedles combining digital light processing and vacuum compression molding technique for the transdermal delivery of rivastigmine

    Monou PK, Saropoulou E, Junqueira LA et al. · European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2025

  17. 0.52

    Tea-derived natural nanodrug simultaneously enables real-time fluorescent tracking and noninvasive treatment of neuroinflammation in Alzheimer's disease

    Qian L, Cui M, Wu M et al. · Journal of nanobiotechnology · 2026

  18. 0.52

    Poly(3-hydroxybutyrate-co-3-hydroxyvalerate-co-3-hydroxyhexanoate)-based microspheres as a sustained platform for Huperzine A delivery for alzheimer's disease therapy

    Wei DX, Cai D, Tan Y et al. · International journal of biological macromolecules · 2024

  19. 0.52

    Brain targeting efficacy of novel drug delivery system in the treatment of Alzheimer's disease

    Duan LH, Li LM, Wang CB et al. · European review for medical and pharmacological sciences · 2024

  20. 0.51

    EphB1-Mediated Transient Blood-Brain Barrier Opening Facilitates a Ferritin-Based Nanotherapeutic for Alzheimer's Disease

    Wen S, Gao J, Wang Z et al. · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026

  21. 0.51

    Synthesis, Properties, and Biomedical Application of Dicationic Gemini Surfactants with Dodecane Spacer and Carbamate Fragments

    Vasileva L, Gaynanova G, Valeeva F et al. · International journal of molecular sciences · 2023

  22. 0.50

    Intramuscularly Administered PLGA Microparticles for Sustained Release of Rivastigmine: In Vitro, In Vivo and Histological Evaluation

    Avendano-Godoy J, Miranda A, Mennickent S et al. · Journal of pharmaceutical sciences · 2023

05review · strategies3편

  1. 0.75

    Effects of Pharmacological Treatments in Alzheimer's Disease: Permutation Entropy-Based EEG Complexity Study

    Fide E, Polat H, Yener G et al. · Brain topography · 2023

  2. 0.61

    Cellular Mechanisms of Cognitive Enhancement: The In Vivo Modulation of the Firing Activity and the Responsiveness of Rat Hippocampal Neurons by Memantine and Alpha7 Nicotinic Acetylcholine Receptor Ligands

    Nagy LV, Bali ZK, Ledneczki I et al. · ASN neuro · 2024

  3. 0.61

    Memory reconsolidation impairment by amyloid beta (1-42) and its prevention by non-competitive antagonists of NMDA receptors

    Tiunova AA, Diffine EA, Anokhin KV · Frontiers in cellular neuroscience · 2025

06molecular dynamics · docking1편

  1. 0.54

    Computational insights and experimental breakthroughs in identifying next-generation acetylcholinesterase inhibitors

    Hanumanthappa D, Kumar BS, Shajan SRO et al. · Scientific reports · 2025

07synthesized · derivatives1편

  1. 0.52

    Can Activation of Acetylcholinesterase by beta-Amyloid Peptide Decrease the Effectiveness of Cholinesterase Inhibitors?

    Zueva IV, Vasilieva EA, Gaynanova GA et al. · International journal of molecular sciences · 2023